Literature DB >> 20421634

Role of urotensin II in health and disease.

Bryan Ross1, Katherine McKendy, Adel Giaid.   

Abstract

Urotensin II (UII) is an 11 amino acid cyclic peptide originally isolated from the goby fish. The amino acid sequence of UII is exceptionally conserved across most vertebrate taxa, sharing structural similarity to somatostatin. UII binds to a class of G protein-coupled receptor known as GPR14 or the urotensin receptor (UT). UII and its receptor, UT, are widely expressed throughout the cardiovascular, pulmonary, central nervous, renal, and metabolic systems. UII is generally agreed to be the most potent endogenous vasoconstrictor discovered to date. Its physiological mechanisms are similar in some ways to other potent mediators, such as endothelin-1. For example, both compounds elicit a strong vascular smooth muscle-dependent vasoconstriction via Ca(2+) release. UII also exerts a wide range of actions in other systems, such as proliferation of vascular smooth muscle cells, fibroblasts, and cancer cells. It also 1) enhances foam cell formation, chemotaxis of inflammatory cells, and inotropic and hypertrophic effects on heart muscle; 2) inhibits insulin release, modulates glomerular filtration, and release of catecholamines; and 3) may help regulate food intake and the sleep cycle. Elevated plasma levels of UII and increased levels of UII and UT expression have been demonstrated in numerous diseased conditions, including hypertension, atherosclerosis, heart failure, pulmonary hypertension, diabetes, renal failure, and the metabolic syndrome. Indeed, some of these reports suggest that UII is a marker of disease activity. As such, the UT receptor is emerging as a promising target for therapeutic intervention. Here, a concise review is given on the vast physiologic and pathologic roles of UII.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421634     DOI: 10.1152/ajpregu.00706.2009

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  42 in total

1.  Urotensin II-induced insulin resistance is mediated by NADPH oxidase-derived reactive oxygen species in HepG2 cells.

Authors:  Ying-Ying Li; Zheng-Ming Shi; Xiao-Yong Yu; Ping Feng; Xue-Jiang Wang
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 2.  Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.

Authors:  R L Juliano; K Carver; C Cao; X Ming
Journal:  J Drug Target       Date:  2012-11-19       Impact factor: 5.121

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Urotensin 2 in Kawasaki disease pathogenesis.

Authors:  Cassidy Y Huang; Jane C Burns; Chisato Shimizu
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

Review 5.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

6.  Insights into the Molecular Determinants Involved in Urocontrin and Urocontrin A Action.

Authors:  Etienne Billard; David Chatenet
Journal:  ACS Med Chem Lett       Date:  2020-08-20       Impact factor: 4.345

7.  Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?

Authors:  M Demirpence; A Guler; H Yilmaz; A Sayin; Y Pekcevik; H Turkon; A Colak; E M Ari; B Aslanipour; G U Kocabas; M Calan
Journal:  J Endocrinol Invest       Date:  2018-05-26       Impact factor: 4.256

8.  Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.

Authors:  D Chatenet; M Létourneau; Q T Nguyen; N D Doan; J Dupuis; A Fournier
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

9.  Urotensin II promotes vagal-mediated bradycardia by activating cardiac-projecting parasympathetic neurons of nucleus ambiguus.

Authors:  Gabriela Cristina Brailoiu; Elena Deliu; Joseph E Rabinowitz; Douglas G Tilley; Walter J Koch; Eugen Brailoiu
Journal:  J Neurochem       Date:  2014-03-06       Impact factor: 5.372

10.  Urotensin receptors as a new target for CLP induced septic lung injury in mice.

Authors:  Elif Cadirci; Rustem Anil Ugan; Busra Dincer; Betul Gundogdu; Irfan Cinar; Erol Akpinar; Zekai Halici
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-24       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.